50 research outputs found
Helicobacter pylori infection of gastric cancercells elevates the level of expression and activation of protein kinase D2
Aim: To test the hypothesis, whether H. pylori infection may affect the level of PKD2 expression and/or activation in gastric cancer cells. Methods: Studies were performed on AGS human gastric adenocarcinoma cell line, gastric tissues samples from 36 cases of different histological variants of gastric cancer. Immunohistochemical, cell and molecular biology, bacteriological and biochemical approaches have been used in this study. Results: H. pylori 16S rRNA gene was detected in 97% cases of gastric tumors, and in 83% of cases cΠ°gA gene was detected. In all tested adenocarcinoma samples cagA+ H. pylori was revealed. These cases were characterized by high level of PKD1/2 expression and autophosphorylation. In adenogenic cancer samples the presence of cagAβ H. pylori was identified. Carcinoid and nondifferentiated gastric cancers contain H. pylori, with very low numbers of cagA+ copies. All cases of gastric tumors with cagAβ H. pylori had very low levels of PKD1/2 autophosphorylation. AGS cell line infection with cagAβ and cagA+ H. Ρylori resulted in elevation of PKD2 expression levels in 3.29 and 3.66 times respectively (p < 0.001). In cells infected by cag+ H. Ρylori the level of PKD2 transphosphorylation was 1.39 higher than in cells infected by cagAβ H. pylori. For PKD2 autophosphorylation this difference was even higher β 3.27 times (p < 0.001). Conclusion: H. pylori infection enhanced the level of protein kinase D2 expression, trans- and autophosphorylation. The level of PKD2 autophosphorylation/activation was higher in AGS cell line inoculated of with cag+ H. pylori than in AGS cells with cagAβ H. pylori. These suggest that H. pylori induces activation of PKD1/2 and could exploit PKD2 mediated signaling pathways that may contribute to the pathogenesis of gastric cancer
Π¦Π΅ΡΠ°Π»ΠΎΡΠΏΠΎΡΠΈΠ½Ρ ΡΡΠ΅ΡΡΠ΅Π³ΠΎ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΡ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π³ΠΎΠ½ΠΎΡΠ΅ΠΈ
The article presents the data on antibiotic resistance and N. gonorrhoeae mechanisms for developing resistance to
antimicrobial drugs belonging to different pharmacologic groups and applied for causal treatment of gonorrhea. The
article proves the key problem related to the treatment of gonococcal infection in Russia lies in the prevalence of strains
being resistant to most of the antibacterial drugs that used to be applied in the clinical practice on a broad scale and
efficiently. So, cephalosporins of the third generation are presently the only drug type that N. gonorrhoeae remains
sensitive to. Their application ensures the maximum efficacy against the gonococcal infection. According to the presentday
international recommendations complying with the WHO criteria as well as accumulated experience, cefixime, a drug
belonging to cephalosporins of the third generation, can be a drug of choice for the antibacterial therapy of gonorrhea
along with ceftriaxon.ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΎ cΠΎΡΡΠΎΡΠ½ΠΈΠΈ Π°Π½ΡΠΈΠ±ΠΈΠΎΡΠΈΠΊΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠ°Ρ
ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΡΡΠΎΠΉΡΠΈΠ²ΠΎΡΡΠΈ
N. gonorrhoeae ΠΊ Π°Π½ΡΠΈΠΌΠΈΠΊΡΠΎΠ±Π½ΡΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π³ΡΡΠΏΠΏ, ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΠΌ
Π΄Π»Ρ ΡΡΠΈΠΎΡΡΠΎΠΏΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π³ΠΎΠ½ΠΎΡΠ΅ΠΈ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΠΎΡΠ½ΠΎΠ²Π½Π°Ρ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π² Π ΠΎΡΡΠΈΠΈ
Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π·Π°ΠΊΠ»ΡΡΠ°Π΅ΡΡΡ Π² ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ ΡΡΠ°ΠΌΠΌΠΎΠ² Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Ρ, ΡΡΡΠΎΠΉΡΠΈΠ²ΡΡ
ΠΊ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Ρ
Π°Π½ΡΠΈΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΡΠ°Π½Π΅Π΅ ΡΠΈΡΠΎΠΊΠΎ ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ²ΡΠΈΡ
ΡΡ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅. ΠΠΎΡΡΠΎΠΌΡ
Π½Π° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ Π΅Π΄ΠΈΠ½ΡΡΠ²Π΅Π½Π½ΡΠΌ ΠΊΠ»Π°ΡΡΠΎΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΠΊ ΠΊΠΎΡΠΎΡΡΠΌ N. gonorrhoeae Π΄ΠΎ ΡΠΈΡ
ΠΏΠΎΡ ΡΠΎΡ
ΡΠ°Π½ΡΠ΅Ρ
ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΡΡΡ
ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ ΠΈΠ·Π»Π΅ΡΠ΅Π½Π½ΠΎΡΡΠΈ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ, ΡΠ²Π»ΡΡΡΡΡ ΡΠ΅ΡΠ°Π»ΠΎΡΠΏΠΎΡΠΈΠ½Ρ ΡΡΠ΅ΡΡΠ΅Π³ΠΎ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΡ. Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠΌ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΠΌ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΡΠΌ
ΠΈ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½Π½ΠΎΠΌΡ ΠΎΠΏΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π²ΡΠ±ΠΎΡΠ° Π΄Π»Ρ Π°Π½ΡΠΈΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π³ΠΎΠ½ΠΎΡΠ΅ΠΈ, ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΡ
ΠΊΡΠΈΡΠ΅ΡΠΈΡΠΌ ΠΠΠ, Π½Π°ΡΡΠ΄Ρ Ρ ΡΠ΅ΡΡΡΠΈΠ°ΠΊΡΠΎΠ½ΠΎΠΌ ΠΌΠΎΠΆΠ΅Ρ ΡΠ²Π»ΡΡΡΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ Π³ΡΡΠΏΠΏΡ ΡΠ΅ΡΠ°Π»ΠΎΡΠΏΠΎΡΠΈΠ½ΠΎΠ² ΡΡΠ΅ΡΡΠ΅Π³ΠΎ ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΡ
Π΄Π»Ρ ΠΏΠ΅ΡΠΎΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΈΠ΅ΠΌΠ° ΡΠ΅ΡΠΈΠΊΡΠΈΠΌ
ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΠ·ΠΎΠ»ΠΈΡΡΡΡΠ΅Π³ΠΎ ΠΊΡΠ΅ΠΌΠ° ΠΠ°ΡΡΠ΅Π΄Π΅ΡΠΌ ΠΏΡΠΈ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ·Π°Ρ
Goal. The aim of the study is evaluation of the effectiveness of a barrier cream Bariederm in combined therapy of dermatoses. Materials and Methods. 3 groups of patients were examined: 32 patients with allergic contact dermatitis, 22 female patients with cold and wind induced dermatitis and 23 children aged 5 years and under with cutaneons mastocytosis. All of them were treated with Bariederm cream. Results. Including of Bariederm cream in combined treatment fetched to increase of clinical efficiency in treatment of dermatoses. Bariederm cream is also well tolerated.Π¦Π΅Π»Ρ. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΠ·ΠΎΠ»ΠΈΡΡΡΡΠ΅Π³ΠΎ ΠΊΡΠ΅ΠΌΠ° ΠΠ°ΡΡΠ΅Π΄Π΅ΡΠΌ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΊΠΎΠΆΠΈ Ρ Π²Π·ΡΠΎΡΠ»ΡΡ
ΠΈ Π΄Π΅ΡΠ΅ΠΉ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ°Π±Π»ΡΠ΄Π°Π»ΠΈ 3 Π³ΡΡΠΏΠΏΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²: 1-Ρ Π³ΡΡΠΏΠΏΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 32 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°, Π±ΠΎΠ»ΡΠ½ΡΡ
Π°Π»Π»Π΅ΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΊΠΎΠ½ΡΠ°ΠΊΡΠ½ΡΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ, Π²ΠΎ 2-Ρ Π³ΡΡΠΏΠΏΡ Π²ΠΎΡΠ»ΠΈ 22 ΠΆΠ΅Π½ΡΠΈΠ½Ρ, ΡΡΡΠ°Π΄Π°Π²ΡΠΈΠ΅ ΠΏΡΠΎΡΡΡΠΌ ΡΠ°Π·Π΄ΡΠ°ΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΈΡΠΎΠΌ ΠΎΡ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π²Π΅ΡΡΠ° ΠΈ Ρ
ΠΎΠ»ΠΎΠ΄Π° Π² Π·ΠΈΠΌΠ½Π΅Π΅ Π²ΡΠ΅ΠΌΡ, Π² 3-Ρ - 23 ΡΠ΅Π±Π΅Π½ΠΊΠ° Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ Π΄ΠΎ 5 Π»Π΅Ρ Ρ ΠΊΠΎΠΆΠ½ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΌΠ°ΡΡΠΎΡΠΈΡΠΎΠ·Π°. Π ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π²ΠΊΠ»ΡΡΠ°Π»ΠΈ ΠΊΡΠ΅ΠΌ ΠΠ°ΡΡΠ΅Π΄Π΅ΡΠΌ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΠΊΡΠ΅ΠΌΠ° ΠΠ°ΡΡΠ΅Π΄Π΅ΡΠΌ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΡΠΈΠ²Π΅Π»ΠΎ ΠΊ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΌΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π½ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΡΠ΅ΠΊΡΠ°. ΠΡΠΌΠ΅ΡΠ΅Π½Π° Ρ
ΠΎΡΠΎΡΠ°Ρ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΡ ΠΊΡΠ΅ΠΌΠ° ΠΠ°ΡΡΠ΅Π΄Π΅ΡΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ
Discrimination between Streptococcus pneumoniae and Streptococcus mitis based on sorting of their MALDI mass spectra
AbstractAccurate species-level identification of alpha-hemolytic (viridans) streptococci (VGS) is very important for understanding their pathogenicity and virulence. However, an extremely high level of similarity between VGS within the mitis group (S. pneumoniae, S. mitis, S. oralis and S. pseudopneumoniae) often results in misidentification of these organisms. Earlier, matrix-assisted laser desorption ionizationβtime of flight mass spectrometry (MALDI-TOF MS) has been suggested as a tool for the rapid identification of S. pneumoniae. However, by using Biotyper 3.0 (Bruker) or Vitek MS (bioMΓ©rieux) databases, Streptococcus mitis/oralis species can be erroneously identified as S. pneumoniae. ClinProTools 2.1 software was used for the discrimination of MALDI-TOF mass spectra of 25 S. pneumoniae isolates, 34 S. mitis and three S. oralis. Phenotypical tests and multilocus gene typing schemes for the S. pneumoniae (http://spneumoniae.mlst.net/) and viridans streptococci (http://viridans.emlsa.net/) were used for the identification of isolates included in the study. The classifying model was generated based on different algorithms (Genetic Algorithm, Supervised Neural Network and QuickClassifier). In all cases, values of sensitivity and specificity were found to be equal or close to 100%, allowing discrimination of mass spectra of different species. Three peaks (6949, 9876 and 9975 m/z) were determined conferring the maximal statistical weight onto each model built. We find this approach to be promising for viridans streptococci discrimination
Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymph
Aim: To study the PKD2 expression, autophosphorylation and localization in reactive lymph nodes and tumors of lymphoid tissues. Materials and Methods: Specific antibodies, which recognize PKD1/2 or PKD2 and autophosphorylated PKD1/2, were used for immunohistochemical and biochemical studies of tonsils, reactive lymph nodes, tumor samples of non-Hodgkinβs lymphoma (NHL) and Hodgkinβs lymphoma (HL). Results: Immunohistochemical and biochemical analysis of PKD1 and PKD2 expression showed PKD2 expression in tonsils, reactive lymph nodes and tumor tissues from patients with NHL and HL. Furthermore, we were not able to reveal PKD1 expression in studied lymphoid tissues. In tonsils and reactive lymph nodes the PKD2 expression was detected in T and B cell zones with highest level in germinal centers of lymphoid follicles and the maximum level of autophosphorylation in the light zones of the germinal centers. We found that low level of PKD2 expression and autophosphorylation was characteristic feature for mantle cell lymphomas, Burkittβs lymphomas, and in 50% of CLL/small lymphocytic lymphomas. Lymphoma cells of germinal center origin and with activated B cell phenotype (diffuse large B cell lymphomas, HL) and anaplastic large cells lymphoma demonstrated the high level of PKD2 expression and autophosphorylation. Conclusions: The level of PKD2 expression and autophosphorylation in neoplastic cells corresponds to the expression pattern of this kinase in their normal analogs, and to the level of cell differentiation and activation.Π¦Π΅Π»Ρ: ΠΈΠ·ΡΡΠΈΡΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ, Π°ΡΡΠΎΡΠΎΡΡΠΎΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΡ PKD2 Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΡΡ
Π»ΠΈΠΌΡaΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ² ΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ
Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π°Π½ΡΠΈΡΠ΅Π»Π°, ΡΠ°ΡΠΏΠΎΠ·Π½Π°ΡΡΠΈΠ΅ PKD1/2 ΠΈΠ»ΠΈ PKD2
ΠΈ Π°ΡΡΠΎΡΠΎΡΡΠΎΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ PKD1/2, Π±ΡΠ»ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ Π΄Π»Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ Π±ΠΈΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΊΠ»Π΅ΡΠΎΠΊ
Π½Π΅Π±Π½ΡΡ
ΠΌΠΈΠ½Π΄Π°Π»ΠΈΠ½, ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΡΡ
Π»ΠΈΠΌΡaΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ², Π±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ² ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π΅Ρ
ΠΎΠ΄ΠΆΠΊΠΈΠ½ΡΠΊΠΈΠΌΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌΠΈ
Π»ΠΈΠΌΡΠΎΠΌΠ°ΠΌΠΈ (ΠΠ₯Π) ΠΈ Π»ΠΈΠΌΡΠΎΠΌΠΎΠΉ Π₯ΠΎΠ΄ΠΆΠΊΠΈΠ½Π° (ΠΠ₯). Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΏΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈ Π±ΠΈΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠΌ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ Π²ΡΡΠ²Π»Π΅Π½Π° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ PKD2 Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΌΠΈΠ½Π΄Π°Π»ΠΈΠ½, Π³ΠΈΠΏΠ΅ΡΠΏΠ»Π°Π·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ² ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΡΠΌ ΠΠ₯Π ΠΈ ΠΠ₯. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ PKD1 Π² ΠΈΠ·ΡΡΠ΅Π½Π½ΡΡ
Π½Π°ΠΌΠΈ Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΡ
ΡΠΊΠ°Π½ΡΡ
Π²ΡΡΠ²Π»Π΅Π½Π° Π½Π΅ Π±ΡΠ»Π°. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ
PKD2 Π±ΡΠ»Π° Π²ΡΡΠ²Π»Π΅Π½Π° Π² T- ΠΈ B-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
Π·ΠΎΠ½Π°Ρ
ΠΌΠΈΠ½Π΄Π°Π»ΠΈΠ½ ΠΈ ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΡΡ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ². ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅
Π²ΡΡΠΎΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΎΡΠΌΠ΅ΡΠ°Π»ΡΡ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
Π·Π°ΡΠΎΠ΄ΡΡΠ΅Π²ΡΡ
ΡΠ΅Π½ΡΡΠΎΠ² Π»ΠΈΠΌΡΠΎΠΈΠ΄Π½ΡΡ
ΡΠΎΠ»Π»ΠΈΠΊΡΠ»ΠΎΠ², ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΡΠΉ ΡΡΠΎΠ²Π΅Π½Ρ
Π°ΡΡΠΎΡΠΎΡΡΠΎΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ β Π² ΡΠ²Π΅ΡΠ»ΡΡ
Π·ΠΎΠ½Π°Ρ
Π·Π°ΡΠΎΠ΄ΡΡΠ΅Π²ΡΡ
ΡΠ΅Π½ΡΡΠΎΠ². ΠΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ, ΡΡΠΎ Π½ΠΈΠ·ΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΈ Π°ΡΡΠΎΡΠΎΡΡΠΎΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ
PKD2 ΡΠ²Π»ΡΠ΅ΡΡΡ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΠΎΠΉ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ Π»ΠΈΠΌΡΠΎΠΌ ΠΈΠ· ΠΊΠ»Π΅ΡΠΎΠΊ ΠΌΠ°Π½ΡΠΈΠΉΠ½ΠΎΠΉ Π·ΠΎΠ½Ρ, Π»ΠΈΠΌΡΠΎΠΌΡ ΠΠ΅ΡΠΊΠΈΡΡΠ°,
Π² 50% ΡΠ»ΡΡΠ°ΡΡ
Π»ΠΈΠΌΡΠΎΠΌ ΠΈΠ· ΠΌΠ°Π»ΡΡ
Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ²/Π₯ΠΠ. ΠΠ»Π΅ΡΠΊΠΈ Π»ΠΈΠΌΡΠΎΠΌ, Π²ΠΎΠ·Π½ΠΈΠΊΠ°ΡΡΠΈΡ
ΠΈΠ· ΠΊΠ»Π΅ΡΠΎΠΊ Π·Π°ΡΠΎΠ΄ΡΡΠ΅Π²ΡΡ
ΡΠ΅Π½ΡΡΠΎΠ² Ρ
ΡΠ΅Π½ΠΎΡΠΈΠΏΠΎΠΌ Π°ΠΊΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
B-ΠΊΠ»Π΅ΡΠΎΠΊ (Π΄ΠΈΡΡΡΠ·Π½Π°Ρ Π»ΠΈΠΌΡΠΎΠΌΠ° ΠΈΠ· ΠΊΡΡΠΏΠ½ΡΡ
B-ΠΊΠ»Π΅ΡΠΎΠΊ, ΠΠ₯), Π° ΡΠ°ΠΊΠΆΠ΅ Π°Π½Π°ΠΏΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΡΡΠΏΠ½ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½Π°Ρ
Π»ΠΈΠΌΡΠΎΠΌΠ° Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°Π»ΠΈΡΡ Π²ΡΡΠΎΠΊΠΈΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΈ Π°ΡΡΠΎΡΠΎΡΡΠΎΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ PKD2. ΠΡΠ²ΠΎΠ΄Ρ: ΡΡΠΎΠ²Π΅Π½Ρ
ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΈ Π°ΡΡΠΎΡΠΎΡΡΠΎΡΠΈΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ PKD2 Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΠ΅Ρ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΡΡΠΈΡ
ΠΊΠΈΠ½Π°Π· Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΡ
Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΡ
Π°Π½Π°Π»ΠΎΠ³Π°Ρ
, ΡΡΠΎΠ²Π½Ρ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ ΠΈΡ
Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ
PNEUMOCOCCAL INFECTION β IN THE CENTRE OF ATTENTION AGAIN
This article present a general review on pneumococcal infection, its prevalence, clinic types in children in Russia and worldwide. Description of S. pneumoniae serotypes' distribution and its influence at clinical manifestation of pneumococcal infection and vaccination effectiveness is provided. Author evaluates perspectives of pneumococcal infection prevention by vaccination with pneumococcal conjugated 7-valent vaccine in Russia.Key words: children, pneumococcal infection, vaccination, pneumococcal conjugated 7 valent vaccine.(Voprosy sovremennoi pediatrii β Current Pediatrics. 2009;8(3):82-87)</em
PNEUMOCOCCAL INFECTION β IN THE CENTRE OF ATTENTION AGAIN
This article present a general review on pneumococcal infection, its prevalence, clinic types in children in Russia and worldwide. Description of S. pneumoniae serotypes' distribution and its influence at clinical manifestation of pneumococcal infection and vaccination effectiveness is provided. Author evaluates perspectives of pneumococcal infection prevention by vaccination with pneumococcal conjugated 7-valent vaccine in Russia.Key words: children, pneumococcal infection, vaccination, pneumococcal conjugated 7 valent vaccine.(Voprosy sovremennoi pediatrii β Current Pediatrics. 2009;8(3):82-87